JP2006500401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500401A5 JP2006500401A5 JP2004535458A JP2004535458A JP2006500401A5 JP 2006500401 A5 JP2006500401 A5 JP 2006500401A5 JP 2004535458 A JP2004535458 A JP 2004535458A JP 2004535458 A JP2004535458 A JP 2004535458A JP 2006500401 A5 JP2006500401 A5 JP 2006500401A5
- Authority
- JP
- Japan
- Prior art keywords
- bisphosphonate
- pharmaceutical composition
- cancer cell
- hmg
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122361 Bisphosphonate Drugs 0.000 claims description 23
- 150000004663 bisphosphonates Chemical class 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000009702 cancer cell proliferation Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 231100000405 induce cancer Toxicity 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 4
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 description 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- NPLHDPAQRZJWHX-UHFFFAOYSA-N [5,5-bis(diethoxyphosphoryl)-1,4-dihydropyrazol-3-yl]-phenylmethanone Chemical class N1C(P(=O)(OCC)OCC)(P(=O)(OCC)OCC)CC(C(=O)C=2C=CC=CC=2)=N1 NPLHDPAQRZJWHX-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- -1 pyridinium salts Chemical class 0.000 description 2
- RDFHOSXBGDLRQF-UHFFFAOYSA-N (2-anilino-1-phosphono-2-sulfanylideneethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)C(=S)NC1=CC=CC=C1 RDFHOSXBGDLRQF-UHFFFAOYSA-N 0.000 description 1
- HLNJFEXZDGURGZ-UHFFFAOYSA-M 1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1 HLNJFEXZDGURGZ-UHFFFAOYSA-M 0.000 description 1
- NEAHTABRXFKZGG-UHFFFAOYSA-N 2-pyridin-4-yl-3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=CC(C=2NC3=CN=CC=C3N=2)=C1 NEAHTABRXFKZGG-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- VADUXZPJGJBSLQ-UHFFFAOYSA-N [1-hydroxy-3-(1-methylpyridin-1-ium-3-yl)-1-phosphonopropyl]phosphonic acid;hydroxide Chemical compound [OH-].C[N+]1=CC=CC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C1 VADUXZPJGJBSLQ-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- JFGHPLSPUGOSLV-UHFFFAOYSA-L disodium;[3-(dimethylamino)-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].CN(C)CCC(O)(P(O)(O)=O)P([O-])([O-])=O JFGHPLSPUGOSLV-UHFFFAOYSA-L 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0220885.8A GB0220885D0 (en) | 2002-09-09 | 2002-09-09 | Organic compounds |
| PCT/EP2003/009972 WO2004024165A1 (en) | 2002-09-09 | 2003-09-08 | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500401A JP2006500401A (ja) | 2006-01-05 |
| JP2006500401A5 true JP2006500401A5 (enExample) | 2006-10-26 |
Family
ID=9943733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535458A Pending JP2006500401A (ja) | 2002-09-09 | 2003-09-08 | ビスホスホネートおよびｈｍｇ−ｃｏａレダクターゼインヒビターを含む組合せ治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060234985A1 (enExample) |
| EP (1) | EP1539186A1 (enExample) |
| JP (1) | JP2006500401A (enExample) |
| CN (1) | CN1327844C (enExample) |
| AU (1) | AU2003270154A1 (enExample) |
| BR (1) | BR0314081A (enExample) |
| CA (1) | CA2497182A1 (enExample) |
| GB (1) | GB0220885D0 (enExample) |
| WO (1) | WO2004024165A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327742D0 (en) * | 2003-11-28 | 2003-12-31 | Isis Innovation | Novel uses of known drugs |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US7687482B2 (en) | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| BRPI0821962A2 (pt) * | 2008-01-03 | 2019-05-07 | Univ De La Mediterrannee Aix Marseille Ii | composições e métodos usados durante um tratamento anti-hiv |
| ES2339524B1 (es) * | 2008-08-28 | 2011-03-22 | Proyecto De Biomedicina Cima, S.L. | Nuevo biomarcador como diana terapeutica en cancer de pulmon. |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| EP2533764A4 (en) * | 2010-02-08 | 2016-08-31 | Univ Nebraska | BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| US20010025028A1 (en) * | 1998-03-13 | 2001-09-27 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
| JP2002506030A (ja) * | 1998-03-13 | 2002-02-26 | メルク エンド カムパニー インコーポレーテッド | 骨再吸収の阻害方法 |
| YU68900A (sh) * | 1998-05-12 | 2002-12-10 | Warner-Lambert Company | Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AU2002213050A1 (en) * | 2000-10-06 | 2002-04-15 | F. Timothy Guilford | A combination and method of treatment of cancer utilizing a cox-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa) reductase inhibitor |
-
2002
- 2002-09-09 GB GBGB0220885.8A patent/GB0220885D0/en not_active Ceased
-
2003
- 2003-09-08 JP JP2004535458A patent/JP2006500401A/ja active Pending
- 2003-09-08 CN CNB038213338A patent/CN1327844C/zh not_active Expired - Fee Related
- 2003-09-08 CA CA002497182A patent/CA2497182A1/en not_active Abandoned
- 2003-09-08 AU AU2003270154A patent/AU2003270154A1/en not_active Abandoned
- 2003-09-08 EP EP03750497A patent/EP1539186A1/en not_active Withdrawn
- 2003-09-08 BR BR0314081-4A patent/BR0314081A/pt not_active IP Right Cessation
- 2003-09-08 WO PCT/EP2003/009972 patent/WO2004024165A1/en not_active Ceased
- 2003-09-08 US US10/526,282 patent/US20060234985A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/431,347 patent/US20090209493A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003133773A (ru) | Фармацевтическое применение бисфосфонатов | |
| JP2006506365A5 (enExample) | ||
| JP4722375B2 (ja) | ビホスホネートの投与法 | |
| JP2006500401A5 (enExample) | ||
| JP2004528340A5 (enExample) | ||
| ZA200303247B (en) | Use of bisphosphonates for pain treatment. | |
| US20090209493A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
| CA2501381A1 (en) | Method of administering bisphosphonates | |
| JP2005247873A5 (enExample) | ||
| RU2003100503A (ru) | Способ введения бисфосфонатов | |
| EP1591122A1 (en) | Method of administering bisphosphonates | |
| JP4692283B2 (ja) | 悪性黒色腫治療剤 | |
| RU2001133352A (ru) | Применение бисфосфоновых кислот для лечения ангиогенеза | |
| HK1080734B (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
| HK1072539B (en) | Use of bisphosphonates in the preparation of a medicment for the treatment of conditings of abnormally increased bone turnover |